{
    "relation": [
        [
            "Citing Patent",
            "US4692453 *",
            "US5262422 *",
            "US5449778 *",
            "US6057334 *",
            "US6380217 *",
            "US6683087 *",
            "US6998405",
            "US8334298",
            "USRE42802",
            "USRE43244",
            "EP0659430A1 *",
            "WO1990000896A1 *"
        ],
        [
            "Filing date",
            "Nov 13, 1985",
            "Feb 19, 1993",
            "Sep 8, 1994",
            "Jul 7, 1997",
            "Mar 27, 2000",
            "Apr 17, 2001",
            "Dec 18, 2003",
            "Apr 24, 2006",
            "Apr 25, 2007",
            "Nov 12, 2010",
            "Dec 19, 1994",
            "Jul 13, 1989"
        ],
        [
            "Publication date",
            "Sep 8, 1987",
            "Nov 16, 1993",
            "Sep 12, 1995",
            "May 2, 2000",
            "Apr 30, 2002",
            "Jan 27, 2004",
            "Feb 14, 2006",
            "Dec 18, 2012",
            "Oct 4, 2011",
            "Mar 13, 2012",
            "Jun 28, 1995",
            "Feb 8, 1990"
        ],
        [
            "Applicant",
            "Sandoz Ltd.",
            "Sandoz Ltd.",
            "Warner-Lambert Company",
            "Novartis Ag",
            "Millennium Pharmaceuticals, Inc.",
            "Axon Biochemicals B.V.",
            "H. Lundbeck A/S",
            "Ferring International Center S.A.",
            "H. Lundbeck A/S",
            "H. Lundbeck A/S",
            "Sandoz Ltd.",
            "Sandoz Ag"
        ],
        [
            "Title",
            "Pharmaceutical active 1,2,3,4,4A,5,10,10A-octahydrobenzo[g] quinoline derivatives, and their use",
            "Octahydrobenzo[g]quinoline",
            "Cyclic amino acids and derivatives thereof",
            "Benzo[g]quinoline derivatives",
            "Methods for controlling GGT-positive bacteria",
            "Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use",
            "Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use",
            "Treatment or prevention of ovarian hyperstimulation syndrome (OHSS) using a dopamine agonist",
            "Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use",
            "Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use",
            "Use of benzo[g]quinolines in the treatment of glaucoma and for the prevention of progressive atrophy of the optic nerve",
            "USE OF BENZO(g)QUINOLINES IN TREATMENT OF NICOTINE ADDICTION"
        ]
    ],
    "pageTitle": "Patent US4565818 - Pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline ... - Google Patents",
    "title": "",
    "url": "http://www.google.com/patents/US4565818?dq=7,053,767",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 7,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988922.24/warc/CC-MAIN-20150728002308-00295-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 485790815,
    "recordOffset": 485763703,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{88856=In particular they exhibit prolactin secretion inhibiting activity as indicated by inhibition of pregnancy (ovum implantation) on administration to female rats on the 5th day after insemination, at dosages of from 0.01 to 3.0 mg/kg s.c., as well as by reduction of serum prolactin levels as measured by RIA, 4 hours after administration to male rats at dosages of from 0.001 to 0.1 mg/kg s.c. [both tests carried out in accordance with the methods described in Experientia 34, 1330 (1978)].}",
    "textBeforeTable": "Patent Citations Pharmaceutical compositions in accordance with 3. above may be prepared employing conventional techniques known in the galenic art. Suitable galenic forms for administration include e.g. tablets and capsules. 3. A pharmaceutical composition comprising a benzo[g]quinoline, ester or salt as defined under 1. above, together with a pharmaceutically acceptable diluent or carrier therefore. 2. A method of treating conditions or disorders having an aetiology comprising or associated with prolactin secretion, in particular a condition or disorder as specified under 1.1.1 above, or a method of treating Morbus Parkinson, or a method for the prophylaxis or treatment of a condition or disorder as specified under 1.3.1 above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a benzo[g]quinoline, ester or salt as defined under 1. above; as well as 1.3.1 for the treatment or prophylaxis of coronary disease, especially congestive heart failure, as well as for the treatment of hypertension or oliguric renal failure; 1.3 as a dopamine receptor stimulating agent, in particular 1.2.1 for use as in the treatment of Morbus Parkinson; and 1.2 a dopaminergic agent, in particular 1.1.1 for use in the treatment of galactorrhoea, premenstrual disorders, hyperprolactinaemic hypogonadism or prolactinoma or for use as a lactation inhibitor; 1.1 a prolactin secretion inhibitor, in particular 1. A 6- and/or 7-oxy-trans-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline in which the 3-position is substituted by an optionally amidated carboxy group, an optionally etherified",
    "textAfterTable": "10 Walsh, et al., J. Org. Chem. 39 (25), 3705-3708 (1974). * Cited by examiner Referenced by Citing Patent Filing date Publication date Applicant Title US4692453 * Nov 13, 1985 Sep 8, 1987 Sandoz Ltd. Pharmaceutical active 1,2,3,4,4A,5,10,10A-octahydrobenzo[g] quinoline derivatives, and their use US5262422 * Feb 19, 1993 Nov 16, 1993 Sandoz Ltd. Octahydrobenzo[g]quinoline US5449778 * Sep 8, 1994 Sep 12, 1995 Warner-Lambert Company Cyclic amino acids and derivatives thereof US6057334 * Jul 7, 1997 May 2, 2000 Novartis Ag Benzo[g]quinoline derivatives US6380217 * Mar 27, 2000 Apr 30, 2002 Millennium Pharmaceuticals, Inc. Methods for controlling GGT-positive bacteria US6683087 * Apr 17, 2001 Jan 27, 2004 Axon Biochemicals B.V. Phenylethylamines and condensed",
    "hasKeyColumn": true,
    "keyColumnIndex": 3,
    "headerRowIndex": 0
}